GlassScriptPhysician profile
Tara J Rizvi
NPI 1467507343
$31,484.77
in general payments reported to CMS, 2019-2025
42 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,021 · 2020: $556 · 2021: $1,188 · 2022: $1,643 · 2023: $7,667 · 2024: $2,616 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $8,664 · Travel and Lodging: $832 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,468.75 |
| Food and Beverage | $8,663.66 |
| Travel and Lodging | $832.22 |
| Education | $112.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18,896.76 | 2019-2025 | |
| Amgen INC. | $2,460.87 | 2019-2025 | Evenity, Tavneos, Otezla |
| Abbvie INC. | $1,439.08 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,313.28 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,271.37 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $1,093.47 | 2019-2025 | Benlysta, Nucala |
| Pfizer INC. | $639.62 | 2019-2025 | |
| Horizon Therapeutics Plc | $566.75 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $538.62 | 2019-2024 | Taltz |
| Astrazeneca Pharmaceuticals LP | $437.16 | 2021-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $421.44 | 2022-2025 | Lupkynis |
| Tersera Therapeutics LLC | $240.40 | 2022-2024 | Quzyttir |
| Alexion Pharmaceuticals, INC. | $221.57 | 2021-2025 | Strensiq, Ultomiris |
| Ani Pharmaceuticals, INC. | $217.23 | 2023-2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $190.97 | 2024-2025 | Acthar |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.